This inventor holds 1 USPTO granted patent. Top assignee: Other. Active years: 2001.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2001
Title: Innovations by Insu P Lee in Treating Hyperplasia
Introduction
Insu P Lee is a notable inventor based in Seoul, South Korea. He has made significant contributions to the field of medical treatments, particularly in addressing hyperplasia caused by the papilloma virus. His innovative approach focuses on utilizing tea catechins, which are known for their safety and ease of administration.
Latest Patents
Insu P Lee holds a patent for a method of treating hyperplasia. This method involves the concomitant topical and oral administration of at least one tea catechin. The use of tea catechins is advantageous as they do not involve the risk of side effects and can be easily administered by patients themselves. This patent highlights the potential for a safer and more accessible treatment option for individuals affected by hyperplasia.
Career Highlights
Throughout his career, Insu P Lee has demonstrated a commitment to advancing medical treatments. His work has led to the development of innovative solutions that prioritize patient safety and ease of use. With a focus on research and development, he continues to explore new avenues for improving health outcomes.
Collaborations
Insu P Lee has collaborated with notable colleagues in his field, including Shu Jun Cheng and De Chang Wang. These partnerships have contributed to the advancement of his research and the successful development of his patented methods.
Conclusion
Insu P Lee's contributions to the treatment of hyperplasia through the use of tea catechins represent a significant advancement in medical innovation. His work not only emphasizes patient safety but also showcases the potential for effective self-administration of treatments. The impact of his inventions is likely to resonate within the medical community for years to come.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile